BioAtla Inc
(NASDAQ:BCAB)
$1.79
-0.18[-9.14%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$1.85
0.0600[3.35%]
Open1.960Close1.790
Vol / Avg.376.146K / 340.211KMkt Cap85.568M
Day Range1.780 - 1.99052 Wk Range1.930 - 11.710

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

BioAtla Stock (NASDAQ:BCAB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$75.00

Lowest Price Target1

$8.00

Consensus Price Target1

$30.18

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
82100

Analyst Firms Making Recommendations1

  • JP Morgan
  • JMP Securities
  • EF Hutton
  • HC Wainwright & Co.
  • BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for BioAtla

All Ratings (27)

Upgrades (0)

Downgrades (1)

Initiations (8)

Q

What is the target price for BioAtla (BCAB)?

A

The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on August 2, 2023. The analyst firm set a price target for $17.00 expecting BCAB to rise to within 12 months (a possible 849.72% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BioAtla (BCAB)?

A

The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.

Q

Is the Analyst Rating BioAtla (BCAB) correct?

A

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $19.00 to $17.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.